Christopher Duma

Allen Institute for Brain Science — United States

Medicine · Health Sciences

27h-index3.8kcitations80works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(22), Immunotherapy and Immune Responses(20), Neurological disorders and treatments(12), Meningioma and schwannoma management(12), Cancer Research and Treatments(11)

Publications80 total

Ventriculoperitoneal shunt management in patients with normal pressure hydrocephalus and cerebral atrophy
JAAPA·2026
Early results of a "First‐in‐Human" Phase 1 clinical study of intracerebroventricular injections of ex vivo expanded, autologous, Wnt‐activated, adipose‐derived stem cells in participants with mild to moderate Alzheimer's Disease (AD)
Alzheimer s & Dementia·2025Open Access
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival
Human Vaccines & Immunotherapeutics·2025· 3 citedOpen Access
Interim Results of a "First-in-Human" Phase 1 Clinical Study of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous, Wnt-Activated, Adipose-Derived Stem Cells in Participants with Mild to Moderate Alzheimer's Disease
Cytotherapy·2025
Intracerebroventricular Injection of Autologous Adipose-Derived Stem Cells for the Treatment of Alzheimer’s Disease: Experience with the First of Three, 3-patient Cohorts in a “First-in-Human” Phase 1 FDA Trial (P12-3.005)
Neurology·2025
Intracerebroventricular injection of autologous, Wnt‐activated, adipose‐derived stem cells for the treatment of Alzheimer’s Disease: Experience with the first patient of a “First in Human” Phase 1 FDA trial
Alzheimer s & Dementia·2024Open Access
Occupational impact of tardive dyskinesia (TD): Survey assessing perceptions and experiences of patients with TD and physicians who treat TD
Parkinsonism & Related Disorders·2024
Burden and management of tardive dyskinesia (TD): An international survey to assess the perceptions and experiences of patients with TD
Parkinsonism & Related Disorders·2024
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Journal of Experimental & Clinical Cancer Research·2022· 46 citedOpen Access
Phase 2 Study of AV-GBM-1 (a Tumor-initiating Cell Targeted Dendritic Cell Vaccine) in Newly Diagnosed Glioblastoma Patients: Safety and Efficacy Assessment
Research Square (Research Square)·2022· 1 citedOpen Access
Abstract CT571: Plasma proteomic markers prognostic or predictive for survival of patients with newly diagnosed glioblastoma who were treated in a phase II trial with standard care and the addition of the novel patient-specific dendritic cell vaccine AV-GBM-1
Cancer Research·2022
CTIM-33. PHASE II TRIAL OF VACCINE IMMUNOTHERAPY IN PRIMARY GLIOBLASTOMA: ADJUNCTIVE AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE FROM IRRADIATED SELF-RENEWING AUTOLOGOUS TUMOR CELLS (AV-GBM-1)
Neuro-Oncology·2021· 1 citedOpen Access
331 Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts·2021Open Access
952 Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma
2021· 3 citedOpen Access
336 Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts·2021Open Access
335 Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts·2021Open Access
333 Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts·2021Open Access
332 Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts·2021Open Access
Early Experience With Virtual and Synchronized Augmented Reality Platform for Preoperative Planning and Intraoperative Navigation: A Case Series
Operative Neurosurgery·2021· 53 citedOpen Access
Results of three or more Gamma Knife radiosurgery procedures for recurrent trigeminal neuralgia
Journal of neurosurgery·2021· 14 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Oleg V. Kopyov(14), L. Dade Lunsford(10), Douglas Kondziolka(8), Robert O. Dillman(8), John C. Flíckinger(7), Brian Copcutt(7), Robert Aiken(6), Daniela A. Bota(6), David Mathieu(5), Santosh Kesari(5), David Piccioni(5), Deane B. Jacques(5), Abraham Lieberman(5), Renato V. LaRocca(4), Ronald F. Young(3), Skip Jacques(3), Kaaren S. Eagle(3), Halle K. Farokhi(3), Jason P. Sheehan(3), Heyoung L. McBride(3)